Babies in the Womb May Already Be Learning LanguageVideo
Some Doctors Prescribe Antibiotics Because Parents Want Them
What Kids Wear Could Determine How Much Exercise They Get
Few College Students Have Received the H1N1 Vaccine
Night Lights Could Lead to Depression
Cervarix Has Been Approved by the FDA
The FDA Is Studying the Effects of Lasik Surgery
Painkillers Can Dull the Effects of Childhood Vaccines
Childbirth May Becoming More Complicated
Botox Sponges Might Help Nose Allergies
The FDA Advises on How to Properly Dispose of Medicine
A French Study Shows Cell Phones Do Not Affect Humans
MRIs May Lead to More Back Surgery
Your More Likely to Wash Your Hands If Someone's Watching
Co-Sleeping Is a Leading Cause of SIDSCategories
- Allergy
- Alzheimer's Disease
- Arthritis
- Asthma
- Breast Cancer
- Cardio Health
- Cholesterol
- Cold and Flu
- Colon Cancer
- Diabetes
- Dieting
- Epilepsy
- Hair Loss
- Headache
- Heartburn
- HIV & AIDS
- Kidney Health
- Leukemia
- Lung Cancer
- Lymphoma
- Multiple Sclerosis
- Men's Health
- Mental Health
- Nutrition
- Osteoporosis
- Parkinson's Disease
- Prostate Health
- Skin Health
- Sleep Disorders
- Women's Health
- General
New Drug Could Work Against Leukemia
Posted on 07/02/2009, 12:00
By -- Robert Preidt
Researchers see promise for treatment of AML and other cancers
THURSDAY, July 2 (HealthDay News) -- A new targeted therapy shows promise in treating acute myeloid leukemia, a highly treatment-resistant blood cancer, according to a new study.
Researchers created an antibody (7G3) that recognizes and binds to a molecule called CD123, which is expressed at high levels on leukemia stem cells (LSCs), but not on normal blood cells. LSCs are cells that can cause acute myeloid leukemia (AML) and are critical for its long-term growth.
When AML-LSCs from human patients were transplanted into mice, those treated with 7G3 survived longer than mice that didn't receive the antibody. The researchers found that 7G3 blocked a signaling pathway in tumor cells, impaired migration of AML-LSCs to bone marrow and activated the immune system to destroy AML-LSCs.
The findings, published in the July 2 issue of the journal Cell Stem Cell, hold promise for future cancer treatments, according to the study authors.
"The recent characterization of defined populations of cancer stem cells in a range of human malignancies, as well as their relative resistance to conventional chemotherapy and radiotherapy, supports the broad applicability of our approach and provides rationale for the progression of AML-LSC-targeted therapeutics from preclinical evaluation to clinical trials," wrote Richard Lock, an associate professor at the Children's Cancer Institute Australia and the University of New South Wales, in a news release.
More information
To learn more about AML, visit the National Cancer Institute.
SOURCE: Cell Press, news release, July 2, 2009
Copyright © 2009 ScoutNews, LLC. All rights reserved.
BigHealthTree.com Disclaimer
Bighealthtree.com Does Not Provide Medical Advice. This site, including the above information, is for informational purposes only and is not a substitute for professional medical or health advice. Always seek the advice of your physician or a qualified health or medical professional before starting any new treatment, changing existing treatment, or altering your current exercise and/or diet program. If you think you are having a medical emergency, call 911 (or the emergency services in your area) or your doctor immediately.
Rating: 3.4 / 5 (5 votes)
 |
 |
Comments (0):
Be the first to comment on this article.
Post a comment